The Neurologic Manifestations of Monkeypox: What Experts Know So Far
The most common symptoms of monkeypox that have neurologic origins may also be related to infectious disease overall.
All articles by Brandon May
Personalized Long-Term Acne Care Recommendations Published
An expert panel provides recommendations to support comprehensive, personalized, long-term treatment strategy that address all presentations of acne and its current and potential future burden.
Identifying Risk Factors for Alzheimer Disease: Are They Modifiable?
Ines Moreno-Gonzalez, PhD, explains how healthy aging can help reduce lifestyle risk factors for Alzheimer disease.
AAD Releases Guideline on Atopic Dermatitis Comorbidities
A new American Academy of Dermatology (AAD) guideline describes available evidence on comorbidities associated with atopic dermatitis in adults.
International Experts Urge Uniformity in Methotrexate Dosing for Psoriasis
An international consensus establishes methotrexate dosing recommendations for psoriasis treatment and identifies current knowledge gaps on the topic.
Stroke-Associated Pneumonia: Risk Factors, Mechanisms, and Interventions
Stroke-associated pneumonia research over the past 2 decades has yielded significant insight into SAP risk factors, diagnostic measures, and management strategies.
Updated CHEST Guidelines on Antithrombotic Therapy in Venous Thromboembolism
The updated CHEST guideline on antithrombotic therapy for VTE includes 4 new PICO questions as well as updated recommendations based on newer evidence.
Does Amoxicillin Benefit Children With Lower Respiratory Tract Infections?
Does the prescription of antibiotics provide a meaningful clinical benefit for children who present with uncomplicated lower respiratory tract infections?
Modifiable Risk Factors and Cognitive Impairment in Patients With Psoriasis
Potential risk factors associated with cognitive impairment in patients with psoriasis are assessed.
Secukinumab vs Adalimumab in Concomitant PsA and Plaque Psoriasis
Secukinumab vs adalimumab for treatment in patients with concomitant plaque psoriasis and active psoriatic arthritis during 52 weeks is reported.
- Loading...
Loading...
Next post in Psoriasis Information Center
Loading... 
Loading...